FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135148499> ?p ?o ?g. }

• W2135148499 endingPage "7819" @default.
• W2135148499 startingPage "7812" @default.
• W2135148499 abstract "The epidermal growth factor receptor (EGFR) is overexpressed in 75 to 90% of renal cell carcinomas and may play a role in tumor initiation and progression. Gefitinib (Iressa, ZD1839) is a potent, selective EGFR-tyrosine kinase inhibitor. This trial was undertaken to assess the efficacy and toxicity of gefitinib in advanced renal cell carcinoma.Oral gefitinib, 500 mg once daily, was given continuously. A single-dose reduction to 250 mg daily was allowed for toxicity. The primary end point was response rate (defined as complete remission + partial remission + stable disease). Secondary end points were progression-free survival, overall survival, toxicity, and correlation of response with EGFR status.Twenty-one patients were enrolled on this study, and all are evaluable for response and toxicity. Patient characteristics were median age 61 (range, 35-78 years); 17 males, 4 females; median performance status 0 (range 0-2); median number of prior systemic therapies 1 (range, 0-3). The median and mean number of cycles of therapy received was 3 and 4.7 (range, 1-14+). The best response was stable disease in eight patients (38%). Median progression-free survival was 2.7 months. Median overall survival was 8.3 months. The difference in overall survival was significantly different between patients with progressive disease versus stable disease (6.1 months versus 16+ months; Log-Rank test P value < 0.0001). Three patients required a dose reduction, all for grade 3 diarrhea. There was no apparent correlation between EGFR status and stability of disease or progression of disease.Gefitinib is without significant conventional activity in renal cell carcinoma. The relation of stable disease to treatment or to disease-related prognostic heterogeneity remains to be defined." @default.
• W2135148499 created "2016-06-24" @default.
• W2135148499 creator A5024145910 @default.
• W2135148499 creator A5026179839 @default.
• W2135148499 creator A5027510751 @default.
• W2135148499 creator A5028817982 @default.
• W2135148499 creator A5037324777 @default.
• W2135148499 creator A5058582830 @default.
• W2135148499 creator A5069513193 @default.
• W2135148499 date "2004-12-01" @default.
• W2135148499 modified "2023-09-27" @default.
• W2135148499 title "A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma" @default.
• W2135148499 cites W1969203269 @default.
• W2135148499 cites W1975579612 @default.
• W2135148499 cites W1984400406 @default.
• W2135148499 cites W2000911303 @default.
• W2135148499 cites W2002359114 @default.
• W2135148499 cites W2002884377 @default.
• W2135148499 cites W2010174111 @default.
• W2135148499 cites W2013670048 @default.
• W2135148499 cites W2019195072 @default.
• W2135148499 cites W2023387637 @default.
• W2135148499 cites W2027960164 @default.
• W2135148499 cites W2037178541 @default.
• W2135148499 cites W2043696829 @default.
• W2135148499 cites W2045508611 @default.
• W2135148499 cites W2049613194 @default.
• W2135148499 cites W2050373003 @default.
• W2135148499 cites W2057567734 @default.
• W2135148499 cites W2057945830 @default.
• W2135148499 cites W2058680827 @default.
• W2135148499 cites W2062366098 @default.
• W2135148499 cites W2103745379 @default.
• W2135148499 cites W2114825062 @default.
• W2135148499 cites W2120718661 @default.
• W2135148499 cites W2126314379 @default.
• W2135148499 cites W2133590033 @default.
• W2135148499 cites W2139248078 @default.
• W2135148499 cites W2140313211 @default.
• W2135148499 cites W2142661339 @default.
• W2135148499 cites W2143813821 @default.
• W2135148499 cites W2146404049 @default.
• W2135148499 cites W2164139770 @default.
• W2135148499 cites W2167368130 @default.
• W2135148499 cites W4293241248 @default.
• W2135148499 cites W93204923 @default.
• W2135148499 doi "https://doi.org/10.1158/1078-0432.ccr-04-0310" @default.
• W2135148499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15585612" @default.
• W2135148499 hasPublicationYear "2004" @default.
• W2135148499 type Work @default.
• W2135148499 sameAs 2135148499 @default.
• W2135148499 citedByCount "99" @default.
• W2135148499 countsByYear W21351484992012 @default.
• W2135148499 countsByYear W21351484992013 @default.
• W2135148499 countsByYear W21351484992014 @default.
• W2135148499 countsByYear W21351484992015 @default.
• W2135148499 countsByYear W21351484992017 @default.
• W2135148499 countsByYear W21351484992018 @default.
• W2135148499 countsByYear W21351484992019 @default.
• W2135148499 countsByYear W21351484992021 @default.
• W2135148499 countsByYear W21351484992022 @default.
• W2135148499 countsByYear W21351484992023 @default.
• W2135148499 crossrefType "journal-article" @default.
• W2135148499 hasAuthorship W2135148499A5024145910 @default.
• W2135148499 hasAuthorship W2135148499A5026179839 @default.
• W2135148499 hasAuthorship W2135148499A5027510751 @default.
• W2135148499 hasAuthorship W2135148499A5028817982 @default.
• W2135148499 hasAuthorship W2135148499A5037324777 @default.
• W2135148499 hasAuthorship W2135148499A5058582830 @default.
• W2135148499 hasAuthorship W2135148499A5069513193 @default.
• W2135148499 hasConcept C121608353 @default.
• W2135148499 hasConcept C126322002 @default.
• W2135148499 hasConcept C126894567 @default.
• W2135148499 hasConcept C143998085 @default.
• W2135148499 hasConcept C203092338 @default.
• W2135148499 hasConcept C2775832928 @default.
• W2135148499 hasConcept C2776694085 @default.
• W2135148499 hasConcept C2776907518 @default.
• W2135148499 hasConcept C2777472916 @default.
• W2135148499 hasConcept C2778822529 @default.
• W2135148499 hasConcept C2779438470 @default.
• W2135148499 hasConcept C2780580887 @default.
• W2135148499 hasConcept C2780739268 @default.
• W2135148499 hasConcept C29730261 @default.
• W2135148499 hasConcept C535046627 @default.
• W2135148499 hasConcept C71924100 @default.
• W2135148499 hasConcept C90924648 @default.
• W2135148499 hasConceptScore W2135148499C121608353 @default.
• W2135148499 hasConceptScore W2135148499C126322002 @default.
• W2135148499 hasConceptScore W2135148499C126894567 @default.
• W2135148499 hasConceptScore W2135148499C143998085 @default.
• W2135148499 hasConceptScore W2135148499C203092338 @default.
• W2135148499 hasConceptScore W2135148499C2775832928 @default.
• W2135148499 hasConceptScore W2135148499C2776694085 @default.
• W2135148499 hasConceptScore W2135148499C2776907518 @default.
• W2135148499 hasConceptScore W2135148499C2777472916 @default.
• W2135148499 hasConceptScore W2135148499C2778822529 @default.
• W2135148499 hasConceptScore W2135148499C2779438470 @default.

• next